Trabodenoson

Research use only, not for human use.

Trabodenoson (INO-8875) is a selective and potent adenosine A1 receptor agonist, an adenosine analog, for the study of primary open-angle glaucoma.

Trabodenoson (INO-8875), an adenosine mimetic, is a highly selective Adenosine A1 receptor agonist. Trabodenoson (INO-8875) is used in the study for Primary Open-Angle Glaucoma.

Trabodenoson treatment significantly increaseS MMP-2 activity and MMP-14 abundance, while decreasing fibronectin and collagen IV expression.

Trabodenoson (6.0%), demonstrating an average IOP drop of 2.45 ± 0.38 mm Hg in young mice over 7 days (downregulation).Topical trabodenoson significantly upregulates nestin expression in the ONH of induced eyes compared with vehicle-treated no-induced eyes.Trabodenoson-treated eyes have significantly reduced optic nerve (ON) edema compared with vehicle-treated eyes. RGC counts are higher in Trabodenoson-treated eyes compared to vehicle (74% versus 47% of the contralateral eye).Animal Model:Young (3-4 months old) and aged (12 months old).Dosage:3% or 6% in 10 μL.Administration:Eye drop for 7 consecutive days.Result:Decreased IOP.Animal Model:Rats.Dosage:3%.Administration:Topical delivery daily.Result:Had significantly reduced optic nerve (ON) edema.

——

GPCR/G Protein

Adenosine Receptor

Adenosine Receptor

——

——

871108-05-3

380.36

C15H20N6O6

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (328.64 mM; Ultrasonic )

O[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@H]([C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12

——

(-20℃)

With Ice Pack

≥ 2 years